Full Text View
Tabular View
No Study Results Posted
Related Studies
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML
This study has been completed.
Study NCT00074737   Information provided by Eleos, Inc.
First Received: December 19, 2003   Last Updated: March 20, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Myelogenous Leukemia
Additional conditions recognized in this trial
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
cenersen sodium (EL625)
Idarubicin
Ara-C
Additional drug interventions recognized in this trial
Cytarabine
More general drug interventions related to this trial
Anti-Infective Agents
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Eleos, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services